Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2229-2236

  Takeuchi, Hiroya ^a   Ozawa, Soji ^a   Ando, Nobutoshi ^a   Shih, Chih Horng ^a   Koyanagi, Kazuo ^a   Ueda, Masakazu ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; DIAGNOSTIC VALUE; ENZYME PHOSPHORYLATION; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031426989     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
2. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
4. Giani, C., and Finocchiaro, G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res., 54: 6338-6339, 1994.
5. Fizzoci, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., and Coco, F. L. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 85: 2685-2690, 1995.
6. Bartsch, D., Shevlin, D. W., Callery, M. P., Norton, J. A., Wells, S. A., Jr., and Goodfellow, P. J. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J. Natl. Cancer Inst. (Bethesda), 88: 680-682, 1996.
7. ink4) in human breast carcinomas. Cancer Res., 54: 5262-5264, 1994.
8. Packenham, J. P., Taylor, J. A., Anna, C. H., White, C. M., and Devereux, T. R. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol. Carcinog., 14: 147-151, 1995.
9. Washimi, O., Nagatake, M, Osada, H., Ueda, R., Koshikawa, T., Seki, T., Takahashi, T., and Takahashi, T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55: 514-517, 1995.
10. Igaki, H., Sasaki, H., Kishi, T., Sakamoto, H., Tachimori, Y., Kato. H., Watanabe, H., Sugimura, T., and Terada, M. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem. Biophys. Res. Commun., 203: 1090-1095, 1994.
11. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zone, J. J., Skolnick, M. H., and Cannon-Albright, L. A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 22-26, 1994.
12. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396-3397, 1994.
13. Maesawa, C., Tamura, G., Nishizuka, S., Ogasawara, S., Ishida, K., Terashima, M., Sakata, K., Sato, N., Saito K., and Satodate R. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res., 56: 3875-3878, 1996.
14. Enders, G. H., Koh, J., Missero, C., Rustgi, A. K., and Harlow, E. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene, 12: 1239-1245, 1996.
15. Fueyo, J., Gomez-Manzano, C., Alfred Yung, W. K., Clayman, G. L., Liu, T. J., Bruner, J., Levin, V. A., and Kyritsis, A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene, 12: 103-110, 1996.
16. INK4 expression is frequent in high-grade gliomas. Cancer Res., 55: 1941-1945, 1995.
17. Fueyo, J., Gomez-Manzano, C., Bruner, J. M., Saito, Y., Zhang, B., Zhang, W., Levin, V. A., Yung, W. K. A., and Kyritsis, A. P. Hypermethylation of the CpG island of the p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene, 13: 1615-1619, 1996.
18. IKN4 gene inactivation in childhood acute lymphocytic leukemia. J. Clin. Oncol., 14: 1512-1520, 1996.
19. Reed, J. A., Loganzo, F., Jr., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W., and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
20. INK4a expression in resected non-small cell lung tumors. Cancer Res., 56: 3415-3420, 1996.
21. Matsushime, H., Roussel, M. F., Ashumun, R. A., and Sherr, C. J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell. 65: 701-713, 1991.
22. Motokura, T., Bloom, T., Kim, H. G., Juppner, H., Ruderman, J. V., Kronenberg, H. M., and Arnold, A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature (Lond.), 350: 512-515, 1991.
23. 1 progression. Oncogene, 9: 2663-2674, 1994.
24. Naito, H., Shibata, J., Kawaguchi, A., Kodama, M., and Hattori, T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol., 146: 1161-1169, 1995.
25. Shinozaki, H., Ozawa, S., Ando, N., Tsuruta, H., Terada, M., Ueda, M., and Kitajima, M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res., 2: 1155-1161, 1996.
26. Jiang, W., Zhang, Y-J., Kahn S. M., Hollstein, M. C., Santella, R. M., Lu, S-H., Harris, C. C., Montesano, R., and Weinstein, B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-9031, 1993.
27. INK4A expression in human breast cancer. Am. J. Pathol., 149: 15-20, 1996.
28. Dei Tos, A. P., Maestro, R., Doglioni, C., Piccinin, S., Libera, D. D., Boiocchi, M., and Fletcher, C. D. M. Tumor suppressor genes and related molecules in leiomyosarcoma. Am. J. Pathol., 148: 1037-1045, 1996.
29. Sakaguchi, M., Fujii, Y., Hirabayashi, H., Yoon, H-E., Komoto, Y., Oue, T., Kusafuka, T., Okada, A., and Matsuda, H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer, 65: 442-445, 1996.
30. Ueki, K., Ono, Y., Henson, J. W., Effird, J. T., Deimling, A. V., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
31. 1 control. Cancer Res., 55: 4818-4823, 1995.
32. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
33. International Union Against Cancer. TNM Classification of Malignant Tumors, Ed. 4, pp. 40-42. New York: Springer-Verlag, 1987.
34. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
35. INK4 cyclin dependent kinase inhibitor in malignant methothelioma. J. Natl. Cancer Inst. (Bethesda). 87: 1870-1875, 1995.
36. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
37. INK4a in oral premalignant lesions. Oncogene, 14: 1799-1803, 1997.
38. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
39. van den Berg, F. M., Baas, I. O., Polak, M. M., and Offerhaus, G. J. A. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am. J. Pathol., 142: 381-385, 1993.
40. Kotelnikov, V. M., Coon, J. S., IV, Mundle, S., Kelanic, S., LaFollete, S., Taylor, S., IV, Hutchinson, J., Panje, W., Caldarelli, D. D., and Preisler, H. D. Cyclin D1 expression in squamous cell carcinomas of the head and neck and oral mucosa in relation to proliferation and apoptosis. Clin. Cancer Res., 3: 95-101, 1997.
41. Nakagawa, K., Conrad, N. K., Williams, J. P., Johnson, B. E., and Kelley, M. J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene, 11: 1843-1851, 1995.